Logo image
Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review
Journal article   Open access   Peer reviewed

Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review

Shumaila M Iqbal, Iqra Qamar, Cassandra Zhi, Anum Nida and Hafiz M Aslam
CUREUS JOURNAL OF MEDICAL SCIENCE, v 11(2), e4146
27 Feb 2019
PMID: 31058029
url
https://doi.org/10.7759/cureus.4146View
Published, Version of Record (VoR)CC BY V4.0 Open

Abstract

Endocrinology/Diabetes/Metabolism Rheumatology
By contrast to clinical trials exploring osteoporosis, clinical trials specifically designed for the osteopenic population are limited. Thus, less clinical data are available regarding treatment benefits and cost-effectiveness of treating a patient population with a bone mass density in the osteopenic range (T-score between -1 and -2.5). In this article, we aimed to highlight this high-risk population with a low bone mass density (BMD) susceptible to high fracture risk by reviewing different national and international guidelines for treating osteopenia. The cost-effectiveness of the therapy for the above-mentioned patient population is also discussed. By reviewing different clinical trials, we have specifically highlighted the role of bisphosphonate therapy for fracture risk reduction and increment in bone mineral density (BMD) in patients with osteopenia.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Endocrinology & Metabolism
Logo image